🟣Tirz | 15mg

TIRZ

Tirz, known as LY3298176, represents a groundbreaking development in the treatment of type 2 diabetes (T2D), introducing a unique dual agonist approach that targets both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual-action mechanism effectively mimics the natural effects of GIP while enhancing cAMP synthesis at GLP-1 receptors, significantly boosting insulin secretion and reducing glucagon levels, outperforming the effects of treatments that target either receptor alone.

With a structure of 39 amino acids and a C20 fatty di-acid moiety, Tirz offers an extended half-life, allowing for a convenient once-weekly dosing regimen that promotes better adherence. Its approval by the FDA in May 2022 for T2D management marks it as the first dual GLP-1 and GIP receptor agonist, highlighting its innovative therapeutic approach.

Tirz efficacy extends beyond glycemic control to include notable benefits in weight management, distinguishing it in clinical trials as superior to existing T2D treatments. Its mechanism involves biased agonism at the GLP-1 receptor, favoring cAMP production, which is believed to enhance its therapeutic effects. Additionally, Tirz influence on adiponectin levels points to potential cardioprotective properties by modulating lipid and glucose metabolism, adipose tissue inflammation, and differentiation.

The ongoing exploration of Tirz in scientific research, driven by its comprehensive benefits in T2D treatment and possible cardiovascular advantages, places it at the forefront of diabetes care. The anticipation for future studies to uncover its long-term impacts and cardiovascular outcomes signifies the medical community's enthusiasm for fully understanding and utilizing Tirz extensive therapeutic potential.

Please be aware that the information provided is based on scientific research and is for educational and informational purposes only. It is the subject of ongoing studies to further understand its potential and applications. Individuals should consult healthcare professionals before considering any peptide for therapeutic use.

OFFICIAL PARTNERS: